



Medical Products Agency

CERTIFICATE NUMBER: 5.9.1-2014-069573

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

Part 1

Issued following an inspection in accordance with:

Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of Sweden confirms the following:

The manufacturer: AstraZeneca AB

Site address: Forskargatan 18, Södertülje, 15185, Sweden

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 2013-02-21, it is considered that it complies with:

The principles of GMP for active substances referred to in Article 47 of Directive 2001/83/EC.

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.



¹ The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

² Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

³ These requirements fulfil the GMP recommendations of WHO.

Part 2

Manufacture of active substance. Names of substances subject to inspection:

ESOMEPRAZOLE SODIUM(en)

FELODIPINE(en)

FORMOTEROL FUMARATE DIHYDRATE(en)

METOPROLOL TARTRATE(en)

METOPROLOL SUCCINATE(en)

TICAGRELOR(en)

TERBUTALINE SULPHATE(en)

OMEPRAZOLE(en)

OMEPRAZOLE SODIUM(en)

OMEPRAZOLE MAGNESIUM(en)

	NUFACTURING OPERATIONS - ACTIVE SUBSTANCES
Active	e Substance : ESOMEPRAZOLE SODIUM
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps:
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing3.6.2 Microbiological testing excluding sterility testing
Active	e Substance : FELODIPINE
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps :
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
	CONTRACTOR OF STREET, LAND STREET, LAND STREET, STREET
3.6	Quality Control Testing



201	e Substance : FORMOTEROL FUMARATE DIHYDRATE
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps :
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for
3.6	identification or traceability (lot numbering) of the active substance) Quality Control Testing
3.0	
	3.6.1 Physical / Chemical testing
Activ	e Substance : METOPROLOL TARTRATE
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps :
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
,	material or container. This also includes any labelling of the material which could be used for
	N
2.7	identification or traceability (lot numbering) of the active substance)
3.6	identification or traceability (lot numbering) of the active substance) Quality Control Testing
3.6	identification or traceability (lot numbering) of the active substance) Quality Control Testing 3.6.1 Physical / Chemical testing
3.6	identification or traceability (lot numbering) of the active substance) Quality Control Testing
	identification or traceability (lot numbering) of the active substance) Quality Control Testing 3.6.1 Physical / Chemical testing
83) 33 (n	identification or traceability (lot numbering) of the active substance) Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing
Activ	identification or traceability (lot numbering) of the active substance) Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing The Substance : METOPROLOL SUCCINATE Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture of active substance intermediates
Activ	identification or traceability (lot numbering) of the active substance) Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing Per Substance: METOPROLOL SUCCINATE Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance
Activ	identification or traceability (lot numbering) of the active substance) Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing The Substance : METOPROLOL SUCCINATE Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture of active substance intermediates
Activ	identification or traceability (lot numbering) of the active substance) Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing Pe Substance: METOPROLOL SUCCINATE Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
Activ	identification or traceability (lot numbering) of the active substance) Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing Per Substance: METOPROLOL SUCCINATE Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps: General Finishing Steps
Activ	identification or traceability (lot numbering) of the active substance) Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing Per Substance: METOPROLOL SUCCINATE Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps: General Finishing Steps 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material)
Activ	identification or traceability (lot numbering) of the active substance) Quality Control Testing 3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing Per Substance: METOPROLOL SUCCINATE Manufacture of Active Substance by Chemical Synthesis 3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps: General Finishing Steps



	identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Activ	e Substance : TICAGRELOR
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps :
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / scaling the active substance within a packaging material
	which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for
3.6	identification or traceability (lot numbering) of the active substance) Quality Control Testing
5.0	
	3.6.1 Physical / Chemical testing
Active	e Substance : TERBUTALINE SULPHATE
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps:
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material
	which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging
	material or container. This also includes any labelling of the material which could be used for
3.6	identification or traceability (lot numbering) of the active substance) Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing excluding sterility testing
Active	Substance : OMEPRAZOLE
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates
	3.1.2 Manufacture of crude active substance
	3.1.3 Salt formation / Purification steps :
3.5	General Finishing Steps
	3.5.1 Physical processing steps :
	Participant (Company) Programme Company Programm



	micronisation 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance)
	3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
The second	3.6.1 Physical / Chemical testing
Active	e Substance : OMEPRAZOLE SODIUM
3.1	Manufacture of Active Substance by Chemical Synthesis
	 3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps :
3.5	General Finishing Steps
	 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
	3.6.2 Microbiological testing excluding sterility testing
Activ	e Substance : OMEPRAZOLE MAGNESIUM
3.1	Manufacture of Active Substance by Chemical Synthesis
A COLUMN	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps:
3.5	General Finishing Steps
	3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing



Clarifying remarks (for public users)

QC analysis can be done at address Forskargutan 18 and Gärtunavägen, Södertälje. (Analys får utföras på Forskargutan 18 och Gärtunavägen, Södertälje.)

2014-09-02

Name and signature of the authorised person of the Competent Authority of Sweden

Mr. Tor Graperg Medical Products Agency

Tel: +46 18 174600 Fax: +46 18 548566

Yo, la suscrita, Anne-Marie Bonde, Notario Público en Estocolmo, Suecia, certifica que TOR GRÅBERG autorizado para firmar en nombre de la LÄKEMEDELSVERKET, LA DIRECCIÓN NACIONAL DE MEDICAMENTOS Y FARMACIA, ha otorgado y firmado el documento que antecede y

Derechos Coronas

440:-

que este documento es una copía correcta.

Estocolmo, 28.05.2015

De oficio:



The Ministry for Foreign Affairs in Stockholm, hereby certifies that

Ms. Anne-Marie Bonde

Notary Public of Stockholm
has issued and signed the foregoing attestation in her official capacity.

Stockholm 1 June 2015

Nr. 10860

Fee Paid 180 SEK

Maria Voldberg



CONSULADO DE CHILE ESTOCOLMO, SUECIA

El Cónsul de Chile que suscribe certifica la
Autenticidad de la firma de don. a
María, Voldberg

Del Ministerio de RR.EE. de Suecia
Actuación No. 1987 Arancel Art. No. 4110

Derechos, US\$ 12 Diferencia 10% 1,2

Total US\$: 13,2 Total SEK. 114.

Andrea Droppelmann V.
Cónsul de Chile





